Rituximab biosimilar - Shanghai CP Guojian Pharmaceutical

Drug Profile

Rituximab biosimilar - Shanghai CP Guojian Pharmaceutical

Alternative Names: CMAB304; Retuxira

Latest Information Update: 20 Aug 2015

Price : $50

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 20 Aug 2015 CMAB 304 is still in phase III development for Diffuse large B cell lymphoma in China (IV), company website mentions drug as soon to be launched product
  • 30 Sep 2006 Phase-III clinical trials in Diffuse large B cell lymphoma in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top